{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:20:28Z","timestamp":1793665228425,"version":"4.5.1"},"reference-count":316,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 AR40864-35"],"award-info":[{"award-number":["R01 AR40864-35"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["2024\/52\/L\/NZ3\/00142"],"award-info":[{"award-number":["2024\/52\/L\/NZ3\/00142"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["2018\/30\/A\/NZ3\/00412"],"award-info":[{"award-number":["2018\/30\/A\/NZ3\/00412"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["2019\/35\/B\/NZ3\/02817"],"award-info":[{"award-number":["2019\/35\/B\/NZ3\/02817"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102759","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:31:46Z","timestamp":1761931906000},"page":"102759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Genetic strategies for therapy of Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"36","author":[{"given":"Agnieszka","family":"\u0141oboda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5687-0839","authenticated-orcid":false,"given":"J\u00f3zef","family":"Dulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102759_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2025.102759_bib2","doi-asserted-by":"crossref","first-page":"988","DOI":"10.7150\/ijms.8391","article-title":"Identification of de novo Mutations of Duch\u00e9nn\u00e8\/Becker Muscular Dystrophies in Southern Spain","volume":"11","author":"Garcia","year":"2014","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.omtn.2025.102759_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omtn.2025.102759_bib4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/mus.10435","article-title":"Origins and early descriptions of \u201cDuchenne muscular dystrophy\u201d","volume":"28","author":"Tyler","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2025.102759_bib5","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1111\/febs.15466","article-title":"The discovery of dystrophin, the protein product of the Duchenne muscular dystrophy gene","volume":"287","author":"Hoffman","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.omtn.2025.102759_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/333466a0","article-title":"The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle","volume":"333","author":"Zubrzycka-Gaarn","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/323646a0","article-title":"Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene","volume":"323","author":"Monaco","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ng0493-283","article-title":"The structural and functional diversity of dystrophin","volume":"3","author":"Ahn","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00439-017-1820-9","article-title":"Normal and altered pre-mRNA processing in the DMD gene","volume":"136","author":"Tuffery-Giraud","year":"2017","journal-title":"Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib11","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.1992.03480190051030","article-title":"Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction. A multicenter study","volume":"267","author":"Chamberlain","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102759_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/humu.24191","article-title":"A single NGS-based assay covering the entire genomic sequence of the DMD gene facilitates diagnostic and newborn screening confirmatory testing","volume":"42","author":"Nallamilli","year":"2021","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2025.102759_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10528-012-9554-9","article-title":"Improved detection of deletions and duplications in the DMD gene using the multiplex ligation-dependent probe amplification (MLPA) method","volume":"51","author":"Sansovi\u0107","year":"2013","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/humu.20831","article-title":"Microarray-based mutation detection in the dystrophin gene","volume":"29","author":"Hegde","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2025.102759_bib15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00438-014-0847-z","article-title":"Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy","volume":"289","author":"Wang","year":"2014","journal-title":"Mol. Genet. Genomics"},{"key":"10.1016\/j.omtn.2025.102759_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0092-8674(88)90383-2","article-title":"The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein","volume":"53","author":"Koenig","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.001782","article-title":"Cardiac Dysfunction in Duchenne Muscular Dystrophy Is Less Frequent in Patients With Mutations in the Dystrophin Dp116 Coding Region Than in Other Regions","volume":"11","author":"Yamamoto","year":"2018","journal-title":"Circ. Genom. Precis. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: one gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2025.102759_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12035-012-8233-5","article-title":"The shortest isoform of dystrophin (Dp40) interacts with a group of presynaptic proteins to form a presumptive novel complex in the mouse brain","volume":"45","author":"Tozawa","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.omtn.2025.102759_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12981-5","article-title":"Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy","volume":"7","author":"Doorenweerd","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102759_bib22","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/nar\/20.7.1725","article-title":"Human and murine dystrophin mRNA transcripts are differentially expressed during skeletal muscle, heart, and brain development","volume":"20","author":"Bies","year":"1992","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102759_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/hmg\/4.3.329","article-title":"Dp140: a novel 140 kDa CNS transcript from the dystrophin locus","volume":"4","author":"Lidov","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-5793(02)02613-3","article-title":"The dystrophin gene is alternatively spliced throughout its coding sequence","volume":"517","author":"Sironi","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtn.2025.102759_bib25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbadis.2006.05.010","article-title":"Dystrophin, its interactions with other proteins, and implications for muscular dystrophy","volume":"1772","author":"Ervasti","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2025.102759_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/345315a0","article-title":"Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle","volume":"345","author":"Ervasti","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1083\/jcb.201212142","article-title":"Cellular and molecular mechanisms underlying muscular dystrophy","volume":"201","author":"Rahimov","year":"2013","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102759_bib28","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1074\/jbc.271.12.6605","article-title":"Ca2+-Calmodulin Binds to the Carboxyl-terminal Domain of Dystrophin","volume":"271","author":"Anderson","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102759_bib29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"10.1016\/j.omtn.2025.102759_bib30","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garc\u00eda-Rodr\u00edguez","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2025.102759_bib32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.39.4.465","article-title":"Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies","volume":"39","author":"Baumbach","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102759_bib33","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1083\/jcb.128.3.355","article-title":"Mechanical function of dystrophin in muscle cells","volume":"128","author":"Pasternak","year":"1995","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102759_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1085\/jgp.201010436","article-title":"Mechanisms of muscle weakness in muscular dystrophy","volume":"136","author":"Goldstein","year":"2010","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.omtn.2025.102759_bib36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.25.12.1111","article-title":"Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber","volume":"25","author":"Mokri","year":"1975","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102759_bib37","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ajpath.2016.01.002","article-title":"Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy","volume":"186","author":"Kuraoka","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2025.102759_bib38","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1073\/pnas.1507719112","article-title":"Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy","volume":"112","author":"Hathout","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib39","doi-asserted-by":"crossref","first-page":"10909","DOI":"10.1074\/jbc.270.18.10909","article-title":"Calpains are activated in necrotic fibers from mdx dystrophic mice","volume":"270","author":"Spencer","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102759_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0960-8966(94)00045-B","article-title":"Phospholipase A2 activity in dystrophinopathies","volume":"5","author":"Lindahl","year":"1995","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102759_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0009-8981(85)90202-5","article-title":"Measurements of calcium and other elements in muscle biopsy samples from patients with Duchenne muscular dystrophy","volume":"147","author":"Jackson","year":"1985","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.omtn.2025.102759_bib42","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1074\/jbc.M006337200","article-title":"Alteration in calcium handling at the subcellular level in mdx myotubes","volume":"276","author":"Robert","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102759_bib43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.biocel.2010.11.005","article-title":"Duchenne muscular dystrophy--what causes the increased membrane permeability in skeletal muscle?","volume":"43","author":"Allen","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102759_bib44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/ars.2017.7435","article-title":"Heme Oxygenase-1 Influences Satellite Cells and Progression of Duchenne Muscular Dystrophy in Mice","volume":"29","author":"Pietraszek-Gremplewicz","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.omtn.2025.102759_bib45","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm.3869","article-title":"Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro\/adipogenic progenitors","volume":"21","author":"Lemos","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nmd.2005.09.009","article-title":"Temporal and spatial mRNA expression patterns of TGF-beta1, 2, 3 and TbetaRI, II, III in skeletal muscles of mdx mice","volume":"16","author":"Zhou","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102759_bib47","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gad.465908","article-title":"Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta\/alternative macrophage activation pathway","volume":"22","author":"Vidal","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.omtn.2025.102759_bib48","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1073\/pnas.80.15.4856","article-title":"Defective myoblasts identified in Duchenne muscular dystrophy","volume":"80","author":"Blau","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib49","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cell.2010.11.039","article-title":"Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx\/mTR mice","volume":"143","author":"Sacco","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib50","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.molmed.2016.04.002","article-title":"Satellite Cells in Muscular Dystrophy - Lost in Polarity","volume":"22","author":"Chang","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13682","article-title":"Intrinsic Muscle Stem Cell Dysfunction Contributes to Impaired Regeneration in the mdx Mouse","volume":"16","author":"Esper","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtn.2025.102759_bib52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13395-019-0207-0","article-title":"miR-146a deficiency does not aggravate muscular dystrophy in mdx mice","volume":"9","author":"Bronisz-Budzy\u0144ska","year":"2019","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2025.102759_bib53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13395-020-00255-0","article-title":"The role of Nrf2 in acute and chronic muscle injury","volume":"10","author":"Bronisz-Budzy\u0144ska","year":"2020","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2025.102759_bib54","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.3390\/molecules20058823","article-title":"Current Understanding of Molecular Pathology and Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy","volume":"20","author":"van Westering","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102759_bib55","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/01.CIR.103.6.864","article-title":"Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin","volume":"103","author":"Loufrani","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102759_bib56","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1161\/ATVBAHA.112.301172","article-title":"Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy","volume":"33","author":"Palladino","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.omtn.2025.102759_bib57","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/01.ATV.0000118683.99628.42","article-title":"Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: total recovery after a treatment with the aminoglycoside gentamicin","volume":"24","author":"Loufrani","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.omtn.2025.102759_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/bbrc.1993.1382","article-title":"Expression of the dystrophin gene in cultured fibroblasts","volume":"192","author":"Hugnot","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","article-title":"Pharmacological advances for treatment in Duchenne muscular dystrophy","volume":"34","author":"Guiraud","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102759_bib60","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102759_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","article-title":"Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?","volume":"16","author":"Kourakis","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtn.2025.102759_bib62","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102759_bib63","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2025.102759_bib64","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s43440-020-00134-x","article-title":"Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future","volume":"72","author":"\u0141oboda","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.omtn.2025.102759_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/genes11080837","article-title":"Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update","volume":"11","author":"Sun","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.omtn.2025.102759_bib66","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.nmd.2021.08.004","article-title":"The DMD gene and therapeutic approaches to restore dystrophin","volume":"31","author":"Fortunato","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102759_bib67","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/349334a0","article-title":"Expression of recombinant dystrophin and its localization to the cell membrane","volume":"349","author":"Lee","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib68","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1085","article-title":"Systemic delivery of genes to striated muscles using adeno-associated viral vectors","volume":"10","author":"Gregorevic","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib69","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1083\/jcb.150.6.1399","article-title":"Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain","volume":"150","author":"Crawford","year":"2000","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102759_bib70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib71","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/4.8.1251","article-title":"Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice","volume":"4","author":"Phelps","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib72","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jacc.2016.02.081","article-title":"Dystrophin-deficient cardiomyopathy","volume":"67","author":"Kamdar","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.omtn.2025.102759_bib73","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","article-title":"Progress toward Gene Therapy for Duchenne Muscular Dystrophy","volume":"25","author":"Chamberlain","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib74","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0006-291X(02)00362-5","article-title":"Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene","volume":"293","author":"Sakamoto","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib75","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.7326\/M23-1073","article-title":"The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence","volume":"176","author":"Bendicksen","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib76","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14712598.2024.2394477","article-title":"The FDA approval of delandistrogene moxeparvovec-rokl for duchenne muscular dystrophy: a critical examination of the evidence and regulatory process","volume":"24","author":"Bhattacharyya","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib77","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2025.102759_bib78","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2024.2776","article-title":"Spending on Targeted Therapies for Duchenne Muscular Dystrophy","volume":"331","author":"Bendicksen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102759_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r1548","article-title":"Duchenne gene therapy halted after three deaths and company u turn","volume":"390","author":"Taylor","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.omtn.2025.102759_bib80","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1126\/science.3055295","article-title":"Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy","volume":"242","author":"Malhotra","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102759_bib81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/aian.AIAN_298_17","article-title":"Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases","volume":"21","author":"Verma","year":"2018","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.omtn.2025.102759_bib82","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nrneurol.2016.180","article-title":"Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line","volume":"12","author":"Dowling","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omtn.2025.102759_bib83","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s43440-020-00134-x","article-title":"Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future","volume":"72","author":"\u0141oboda","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.omtn.2025.102759_bib84","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nrg1180","article-title":"Advances in Duchenne muscular dystrophy gene therapy","volume":"4","author":"van Deutekom","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib85","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib86","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2025.102759_bib87","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2025.102759_bib88","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41582-018-0033-8","article-title":"Why dystrophin quantification is key in the eteplirsen saga","volume":"14","author":"Aartsma-Rus","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omtn.2025.102759_bib89","first-page":"251","article-title":"Dystrophin levels required for genetic correction of Duchenne muscular dystrophy","volume":"7","author":"Chamberlain","year":"1997","journal-title":"Basic Appl. Myol."},{"key":"10.1016\/j.omtn.2025.102759_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ppedcard.2021.101460","article-title":"Genetic correction strategies for Duchenne Muscular Dystrophy and their impact on the heart","volume":"63","author":"Johnston","year":"2021","journal-title":"Prog. Pediatr. Cardiol."},{"key":"10.1016\/j.omtn.2025.102759_bib91","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jgm.1288","article-title":"In vivo comparison of 2\u2019-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping","volume":"11","author":"Heemskerk","year":"2009","journal-title":"J. Gene Med."},{"key":"10.1016\/j.omtn.2025.102759_bib92","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm1345","article-title":"Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology","volume":"12","author":"Alter","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib93","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/mt.2008.52","article-title":"Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle","volume":"16","author":"Townsend","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib94","first-page":"1202","article-title":"Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy","volume":"11","author":"Nguyen","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.omtn.2025.102759_bib95","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","article-title":"Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function","volume":"17","author":"Yin","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib96","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102759_bib97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtn.2022.08.019","article-title":"A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Gan","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102759_bib98","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2025.102759_bib99","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112546119","article-title":"Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy","volume":"119","author":"Lim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/hum.2023.026","article-title":"The Future of Exon Skipping for Duchenne Muscular Dystrophy","volume":"34","author":"Aartsma-Rus","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib102","doi-asserted-by":"crossref","first-page":"11401","DOI":"10.1093\/nar\/gkac641","article-title":"Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice","volume":"50","author":"Desjardins","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102759_bib103","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1212\/WNL.0000000000204511","article-title":"Phase 1\/2 Trial Evaluating AOC 1044 in Healthy Volunteers and Participants with DMD Mutations Amenable to Exon 44 Skipping (DMD44): EXPLORE44 Trial Design (P4-8.007)","volume":"102","author":"Stahl","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102759_bib104","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/nat.2013.0451","article-title":"Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides","volume":"24","author":"Echigoya","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines6010001","article-title":"Skipping Multiple Exons to Treat DMD-Promises and Challenges","volume":"6","author":"Aslesh","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2025.102759_bib106","doi-asserted-by":"crossref","DOI":"10.3791\/53776","article-title":"Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy","author":"Miskew Nichols","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omtn.2025.102759_bib107","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1073\/pnas.1613203114","article-title":"Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy","volume":"114","author":"Echigoya","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib108","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.53094","article-title":"Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine Care","volume":"7","author":"Hong","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.omtn.2025.102759_bib109","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.celrep.2015.07.066","article-title":"TNF-\u03b1-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy","volume":"12","author":"Fiorillo","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2025.102759_bib110","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1152\/physiolgenomics.00134.2017","article-title":"Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone","volume":"50","author":"Fiorillo","year":"2018","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.omtn.2025.102759_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102228","article-title":"Deletion of miR-146a enhances therapeutic protein restoration in model of dystrophin exon skipping","volume":"35","author":"McCormack","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102759_bib112","doi-asserted-by":"crossref","first-page":"9456","DOI":"10.1073\/pnas.142302299","article-title":"Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells","volume":"99","author":"De Angelis","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib113","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1126\/science.1104297","article-title":"Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping","volume":"306","author":"Goyenvalle","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102759_bib114","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s44321-024-00031-3","article-title":"Cell-mediated exon skipping normalizes dystrophin expression and muscle function in a new mouse model of Duchenne Muscular Dystrophy","volume":"16","author":"Galli","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib115","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nm.3628","article-title":"Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice","volume":"20","author":"Wein","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib116","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1089\/hum.2004.15.1065","article-title":"Phase I study of dystrophin plasmid-based gene therapy in Duchenne\/Becker muscular dystrophy","volume":"15","author":"Romero","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib117","doi-asserted-by":"crossref","first-page":"12979","DOI":"10.1073\/pnas.202300099","article-title":"Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin","volume":"99","author":"DelloRusso","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib118","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/104303404772679959","article-title":"Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector","volume":"15","author":"Dudley","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib119","article-title":"Lentiviral vectors can be used for full-length dystrophin gene therapy","volume":"7","author":"Counsell","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102759_bib120","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.cell.2023.03.033","article-title":"Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery","volume":"186","author":"Hindi","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib121","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib122","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib123","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1093\/hmg\/ddr105","article-title":"Therapeutic approaches to muscular dystrophy","volume":"20","author":"Goyenvalle","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib124","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nm1439","article-title":"rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice","volume":"12","author":"Gregorevic","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib125","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","article-title":"Development of Novel Micro-dystrophins with Enhanced Functionality","volume":"27","author":"Ramos","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib126","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0014-5793(98)00251-8","article-title":"Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs","volume":"425","author":"Yuasa","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtn.2025.102759_bib127","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib128","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/sj.mt.6300161","article-title":"Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression","volume":"15","author":"Wang","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib129","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/mt.2012.283","article-title":"Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy","volume":"21","author":"Shin","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib131","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo1815","article-title":"Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy","volume":"15","author":"Birch","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib132","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146511","article-title":"Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model","volume":"6","author":"Howard","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102759_bib133","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.omtm.2023.02.001","article-title":"Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy model","volume":"28","author":"Piepho","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102759_bib134","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221149781","article-title":"Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy","volume":"16","author":"Goedeker","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.omtn.2025.102759_bib135","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib136","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1089\/hum.2024.013","article-title":"Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMDMDX Rats","volume":"35","author":"Baine","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib137","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn4704","article-title":"Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders","volume":"8","author":"El Andari","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102759_bib138","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102759_bib139","doi-asserted-by":"crossref","first-page":"7965","DOI":"10.1038\/s41467-024-52002-4","article-title":"An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species","volume":"15","author":"Vu Hong","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib141","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib142","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity - \u201cone and done\u201d or \u201cslower and lower\u201d","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib143","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1016\/j.ymthe.2025.08.029","article-title":"The future of gene therapy: Safer vectors, sharper focus: High-profile failures demand deep root cause analysis - but the transformative potential of AAV remains within reach if the field is willing to learn and evolve","volume":"33","author":"Chamberlain","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib144","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib145","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne\u2019s Muscular Dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib146","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/hum.2022.180","article-title":"The Implication of Hinge 1 and Hinge 4 in Micro-Dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"34","author":"Wasala","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib147","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0898-6568(01)00236-4","article-title":"The WW domain: linking cell signalling to the membrane cytoskeleton","volume":"14","author":"Ilsley","year":"2002","journal-title":"Cell. Signal."},{"key":"10.1016\/j.omtn.2025.102759_bib148","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1089\/hum.2022.081","article-title":"Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy","volume":"34","author":"Verma","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib149","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/hum.2022.166","article-title":"T Cell Responses to Dystrophin in a Natural History Study of Duchenne Muscular Dystrophy","volume":"34","author":"Anthony","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib150","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1089\/hum.2013.092","article-title":"Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect","volume":"24","author":"Flanigan","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101195","article-title":"Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74","volume":"32","author":"Potter","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102759_bib152","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1016\/j.ymthe.2025.06.032","article-title":"Complement Activation in a Phase Ib Study of Fordadistrogene Movaparvovec for Duchenne Muscular Dystrophy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib153","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1089\/hum.2023.119","article-title":"Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors","volume":"34","author":"Costa-Verdera","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib154","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/nbt1153","article-title":"Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors","volume":"23","author":"Lai","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102759_bib155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/mt.2010.205","article-title":"Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6","volume":"19","author":"Odom","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib156","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1089\/hum.2013.164","article-title":"Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice","volume":"25","author":"Koo","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib157","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1089\/hum.2008.009","article-title":"Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy","volume":"19","author":"Li","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib158","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","article-title":"Split intein-mediated protein trans-splicing to express large dystrophins","volume":"632","author":"Tasfaout","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib159","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib160","doi-asserted-by":"crossref","DOI":"10.1172\/JCI189075","article-title":"Expression of full-length dystrophin reverses muscular dystrophy defects in young and old mdx4cv mice","volume":"135","author":"Tasfaout","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102759_bib161","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1038\/s41467-024-50569-6","article-title":"Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib162","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.1254445","article-title":"Prevention of muscular dystrophy in mice by CRISPR\/Cas9-mediated editing of germline DNA","volume":"345","author":"Long","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102759_bib163","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib164","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/cvr\/cvad182","article-title":"Dysregulated iron homeostasis in dystrophin-deficient cardiomyocytes: correction by gene editing and pharmacological treatment","volume":"120","author":"Andrysiak","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.omtn.2025.102759_bib165","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI136873","article-title":"Correction of muscular dystrophies by CRISPR gene editing","volume":"130","author":"Chemello","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102759_bib166","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8081","article-title":"Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy","volume":"9","author":"Amoasii","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib167","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/JND-170218","article-title":"Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR\/Cas9 Gene Editing Therapy","volume":"4","author":"Young","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2025.102759_bib168","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1038\/srep05635","article-title":"Generation of muscular dystrophy model rats with a CRISPR\/Cas system","volume":"4","author":"Nakamura","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102759_bib169","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.032201","article-title":"A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR\/Cas9","volume":"11","author":"Sui","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtn.2025.102759_bib170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","article-title":"Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy","volume":"26","author":"Moretti","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib171","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s42003-024-06222-5","article-title":"Severe cardiac and skeletal manifestations in DMD-edited microminipigs: an advanced surrogate for Duchenne muscular dystrophy","volume":"7","author":"Otake","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omtn.2025.102759_bib172","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3390\/ijms17101668","article-title":"Porcine Zygote Injection with Cas9\/sgRNA Results in DMD-Modified Pig with Muscle Dystrophy","volume":"17","author":"Yu","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102759_bib173","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1093\/hmg\/ddv120","article-title":"Functional disruption of the dystrophin gene in rhesus monkey using CRISPR\/Cas9","volume":"24","author":"Chen","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib174","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.045369","article-title":"A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic Dmd deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathy","volume":"13","author":"Wong","year":"2020","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtn.2025.102759_bib175","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nbt.3816","article-title":"Highly efficient RNA-guided base editing in mouse embryos","volume":"35","author":"Kim","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102759_bib176","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1602814","article-title":"CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice","volume":"3","author":"Zhang","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102759_bib177","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102759_bib178","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102759_bib179","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib180","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCRESAHA.117.310996","article-title":"In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice","volume":"121","author":"El Refaey","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.omtn.2025.102759_bib181","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4324","article-title":"CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells","volume":"5","author":"Min","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102759_bib182","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124297","article-title":"AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice","volume":"3","author":"Hakim","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102759_bib183","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib184","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ymthe.2019.05.001","article-title":"Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib185","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ymthe.2020.11.003","article-title":"Dystrophin Gene-Editing Stability Is Dependent on Dystrophin Levels in Skeletal but Not Cardiac Muscles","volume":"29","author":"Bengtsson","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib186","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.38","article-title":"Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells","volume":"1","author":"Arnett","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102759_bib187","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41556-017-0010-2","article-title":"ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs","volume":"20","author":"Hicks","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102759_bib188","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013228","article-title":"Targeted genome editing in vivo corrects a Dmd duplication restoring wild-type dystrophin expression","volume":"13","author":"Maino","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib189","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102759_bib190","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","article-title":"Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping","volume":"11","author":"Gee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib191","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/j.ymthe.2022.05.023","article-title":"Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene","volume":"30","author":"Majeau","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib192","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.molcel.2018.09.002","article-title":"Genetic Modulation of RNA Splicing with a CRISPR-Guided Cytidine Deaminase","volume":"72","author":"Yuan","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib193","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg4910","article-title":"Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing","volume":"7","author":"Chemello","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102759_bib194","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nbt.4148","article-title":"Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy","volume":"36","author":"Ryu","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102759_bib195","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1038\/s41467-021-23996-y","article-title":"Efficient precise in vivo base editing in adult dystrophic mice","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib196","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.omtn.2023.04.009","article-title":"Single-swap editing for the correction of common Duchenne muscular dystrophy mutations","volume":"32","author":"Chai","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102759_bib197","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/CIRCULATIONAHA.121.054628","article-title":"Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo","volume":"144","author":"Li","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102759_bib198","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41589-024-01706-1","article-title":"Engineered IscB-\u03c9RNA system with expanded target range for base editing","volume":"21","author":"Xiao","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.omtn.2025.102759_bib199","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162809","article-title":"Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy","volume":"133","author":"Li","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102759_bib200","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1093\/nar\/gkae057","article-title":"Selection-free precise gene repair using high-capacity adenovector delivery of advanced prime editing systems rescues dystrophin synthesis in DMD muscle cells","volume":"52","author":"Wang","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102759_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1128557","article-title":"Prime editing strategies to mediate exon skipping in DMD gene","volume":"10","author":"Happi Mbakam","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib202","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib203","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.ymthe.2022.02.003","article-title":"Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model","volume":"30","author":"Bengtsson","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib204","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/mt.2015.192","article-title":"CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice","volume":"24","author":"Xu","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib205","doi-asserted-by":"crossref","DOI":"10.1038\/srep37051","article-title":"Adenoviral vectors encoding CRISPR\/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells","volume":"6","author":"Maggio","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102759_bib206","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/hum.2023.053","article-title":"CRISPR-Editing Therapy for Duchenne Muscular Dystrophy","volume":"34","author":"Chemello","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib207","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymthe.2023.11.010","article-title":"Casein kinase 2 activity is a host restriction factor for AAV transduction","volume":"32","author":"Kraszewska","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib208","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtn.2025.102759_bib209","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib210","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib211","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib212","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib213","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib214","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1006\/mthe.2001.0496","article-title":"Immune evasion by muscle-specific gene expression in dystrophic muscle","volume":"4","author":"Hartigan-O\u2019Connor","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib215","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.cell.2017.10.025","article-title":"In Vivo Target Gene Activation via CRISPR\/Cas9-Mediated Trans-epigenetic Modulation","volume":"171","author":"Liao","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib216","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012063","article-title":"Trans-generational epigenetic regulation associated with the amelioration of Duchenne Muscular Dystrophy","volume":"12","author":"Martone","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib217","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/339055a0","article-title":"An autosomal transcript in skeletal muscle with homology to dystrophin","volume":"339","author":"Love","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib218","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/360591a0","article-title":"Primary structure of dystrophin-related protein","volume":"360","author":"Tinsley","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib219","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/360588a0","article-title":"Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle","volume":"360","author":"Matsumura","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib220","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/hmg\/2.11.1765","article-title":"The utrophin and dystrophin genes share similarities in genomic structure","volume":"2","author":"Pearce","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib221","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1750-3639.1996.tb00781.x","article-title":"Utrophin: a structural and functional comparison to dystrophin","volume":"6","author":"Blake","year":"1996","journal-title":"Brain Pathol."},{"key":"10.1016\/j.omtn.2025.102759_bib222","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF02388063","article-title":"Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle","volume":"25","author":"Clerk","year":"1993","journal-title":"Histochem. J."},{"key":"10.1016\/j.omtn.2025.102759_bib223","doi-asserted-by":"crossref","first-page":"45285","DOI":"10.1074\/jbc.M205177200","article-title":"A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle","volume":"277","author":"Weir","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102759_bib224","doi-asserted-by":"crossref","first-page":"14025","DOI":"10.1073\/pnas.96.24.14025","article-title":"A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy","volume":"96","author":"Burton","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib225","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/nar\/24.9.1646","article-title":"Molecular and functional analysis of the utrophin promoter","volume":"24","author":"Dennis","year":"1996","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.omtn.2025.102759_bib226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0960-8966(92)90004-P","article-title":"The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies","volume":"2","author":"Helliwell","year":"1992","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102759_bib227","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0092-8674(00)80532-2","article-title":"Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy","volume":"90","author":"Deconinck","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib228","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0092-8674(00)80533-4","article-title":"Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy","volume":"90","author":"Grady","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib229","doi-asserted-by":"crossref","first-page":"S929","DOI":"10.1007\/s100720070006","article-title":"Structural comparison of actin binding in utrophin and dystrophin","volume":"21","author":"Keep","year":"2000","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.omtn.2025.102759_bib230","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41536-018-0045-4","article-title":"Humanizing the mdx mouse model of DMD: the long and the short of it","volume":"3","author":"Yucel","year":"2018","journal-title":"NPJ Regen. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib231","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/hmg\/ddl083","article-title":"Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy","volume":"15","author":"Kleopa","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib232","doi-asserted-by":"crossref","first-page":"23249","DOI":"10.18632\/oncotarget.4021","article-title":"Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy","volume":"6","author":"Levi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2025.102759_bib233","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150818","article-title":"Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies","volume":"11","author":"Janghra","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102759_bib234","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ajmg.1320580403","article-title":"Absence of correlation between utrophin localization and quantity and the clinical severity in Duchenne\/Becker dystrophies","volume":"58","author":"Vainzof","year":"1995","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib235","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","article-title":"Therapeutic approaches for Duchenne muscular dystrophy","volume":"22","author":"Roberts","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102759_bib236","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1021\/jm200135z","article-title":"Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy","volume":"54","author":"Chancellor","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102759_bib237","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/nan.12735","article-title":"Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies","volume":"47","author":"Soblechero-Mart\u00edn","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.omtn.2025.102759_bib238","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113431","article-title":"Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy","volume":"220","author":"Vuorinen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102759_bib239","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1242\/jcs.064808","article-title":"Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin","volume":"123","author":"Li","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omtn.2025.102759_bib240","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/hmg\/ddh087","article-title":"ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan","volume":"13","author":"Ishikawa-Sakurai","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib241","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/nm1197-1216","article-title":"Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice","volume":"3","author":"Deconinck","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib242","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/384349a0","article-title":"Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene","volume":"384","author":"Tinsley","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib243","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/4033","article-title":"Expression of full-length utrophin prevents muscular dystrophy in mdx mice","volume":"4","author":"Tinsley","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib244","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/mt.2008.149","article-title":"Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin\/utrophin-deficient mice","volume":"16","author":"Odom","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib245","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2018.10.005","article-title":"Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2\/mdx Mice","volume":"11","author":"Kennedy","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102759_bib246","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","article-title":"Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models","volume":"25","author":"Song","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib247","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009179","article-title":"Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects","volume":"16","author":"Banks","year":"2020","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib248","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajhg.2015.11.012","article-title":"Spell Checking Nature: Versatility of CRISPR\/Cas9 for Developing Treatments for Inherited Disorders","volume":"98","author":"Wojtal","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib249","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102247","article-title":"Upregulation of utrophin improves the phenotype of Duchenne muscular dystrophy hiPSC-derived CMs","volume":"35","author":"Andrysiak","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102759_bib250","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/ncomms2550","article-title":"An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells","volume":"4","author":"Filareto","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib251","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1093\/hmg\/ddr140","article-title":"The Sleeping Beauty transposon system: a non-viral vector for gene therapy","volume":"20","author":"Aronovich","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib252","doi-asserted-by":"crossref","first-page":"13856","DOI":"10.1073\/pnas.0405972101","article-title":"Heregulin ameliorates the dystrophic phenotype in mdx mice","volume":"101","author":"Krag","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib253","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1091\/mbc.e06-12-1069","article-title":"Ets-2 repressor factor silences extrasynaptic utrophin by N-box mediated repression in skeletal muscle","volume":"18","author":"Perkins","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omtn.2025.102759_bib254","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182676","article-title":"Functional improvement of dystrophic muscle by repression of utrophin: let-7c interaction","volume":"12","author":"Mishra","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102759_bib255","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.omtn.2020.08.031","article-title":"Genome Editing-Mediated Utrophin Upregulation in Duchenne Muscular Dystrophy Stem Cells","volume":"22","author":"Sengupta","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102759_bib256","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76338-1","article-title":"PMO-based let-7c site blocking oligonucleotide (SBO) mediated utrophin upregulation in mdx mice, a therapeutic approach for Duchenne muscular dystrophy (DMD)","volume":"10","author":"Sengupta","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102759_bib257","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.1007\/s00018-021-03862-2","article-title":"The multifaceted view of heart problem in Duchenne muscular dystrophy","volume":"78","author":"Florczyk-Soluch","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2025.102759_bib258","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jama.1996.03530410049032","article-title":"Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies","volume":"275","author":"Politano","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102759_bib259","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3349\/ymj.2011.52.1.192","article-title":"Three cases of manifesting female carriers in patients with Duchenne muscular dystrophy","volume":"52","author":"Song","year":"2011","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.omtn.2025.102759_bib260","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.nmd.2018.04.005","article-title":"Female dystrophinopathy: Review of current literature","volume":"28","author":"Ishizaki","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102759_bib261","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.707838","article-title":"Cardiac Involvement in Women With Pathogenic Dystrophin Gene Variants","volume":"12","author":"Solheim","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omtn.2025.102759_bib262","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/ph8020303","article-title":"X-linked dilated cardiomyopathy: a cardiospecific phenotype of dystrophinopathy","volume":"8","author":"Nakamura","year":"2015","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.omtn.2025.102759_bib263","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.nmd.2004.04.007","article-title":"Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings","volume":"14","author":"Quinlan","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102759_bib264","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/mus.21763","article-title":"Gender influences cardiac function in the mdx model of Duchenne cardiomyopathy","volume":"42","author":"Bostick","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2025.102759_bib265","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yjmcc.2016.11.011","article-title":"Uniform low-level dystrophin expression in the heart partially preserved cardiac function in an aged mouse model of Duchenne cardiomyopathy","volume":"102","author":"Wasala","year":"2017","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.omtn.2025.102759_bib266","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5582\/irdr.2017.01024","article-title":"Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series","volume":"6","author":"Papa","year":"2017","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.omtn.2025.102759_bib267","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/hum.2023.29242.ddu","article-title":"Duchenne Muscular Dystrophy Gene Therapy in 2023: Status, Perspective, and Beyond","volume":"34","author":"Duan","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib268","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/sj.mt.6300144","article-title":"Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure","volume":"15","author":"Townsend","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib269","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/01.CIR.0000089371.11664.27","article-title":"Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart","volume":"108","author":"Yue","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102759_bib270","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/mt.2011.154","article-title":"AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice","volume":"19","author":"Bostick","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib271","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.yjmcc.2012.05.002","article-title":"AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy","volume":"53","author":"Bostick","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.omtn.2025.102759_bib272","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1093\/hmg\/ddt112","article-title":"Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy","volume":"22","author":"Wasala","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib273","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/01.CIR.87.6.1854","article-title":"X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus","volume":"87","author":"Towbin","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102759_bib274","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165869","article-title":"Potential limitations of micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"9","author":"Hart","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102759_bib275","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/hmg\/ddv460","article-title":"Effect of genetic background on the dystrophic phenotype in mdx mice","volume":"25","author":"Coley","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib276","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/364725a0","article-title":"Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity","volume":"364","author":"Cox","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib277","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.45","article-title":"100-fold but not 50-fold dystrophin overexpression aggravates electrocardiographic defects in the mdx model of Duchenne muscular dystrophy","volume":"3","author":"Yue","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102759_bib278","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1016\/j.ymthe.2025.06.031","article-title":"Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial","volume":"33","author":"Sherlock","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib279","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jacbts.2024.12.015","article-title":"Long-Term Dystrophin Replacement Therapy in Duchenne Muscular Dystrophy Causes Cardiac Inflammation","volume":"10","author":"Forand","year":"2025","journal-title":"JACC. Basic Transl. Sci."},{"key":"10.1016\/j.omtn.2025.102759_bib280","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/mt.2008.28","article-title":"Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice","volume":"16","author":"Gregorevic","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib281","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1016\/j.ymthe.2025.07.013","article-title":"AAV-microutrophin gene therapy confers durable cardioprotection against pharmacologic and exercise-induced injury in the mdx mouse","volume":"33","author":"Kasden","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib282","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1093\/hmg\/ddt287","article-title":"Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle","volume":"22","author":"Klymiuk","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib283","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2301250120","article-title":"Systemic deletion of DMD exon 51 rescues clinically severe Duchenne muscular dystrophy in a pig model lacking DMD exon 52","volume":"120","author":"Stirm","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102759_bib284","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.647010","article-title":"Abnormal Calcium Handling in Duchenne Muscular Dystrophy: Mechanisms and Potential Therapies","volume":"12","author":"Mareedu","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.omtn.2025.102759_bib285","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ymthe.2019.12.011","article-title":"Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy","volume":"28","author":"Wasala","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib286","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101268","article-title":"SERCA2a overexpression improves muscle function in a canine Duchenne muscular dystrophy model","volume":"32","author":"Kodippili","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102759_bib287","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027480","article-title":"Dwarf Open Reading Frame (DWORF) Gene Therapy Ameliorated Duchenne Muscular Dystrophy Cardiomyopathy in Aged mdx Mice","volume":"12","author":"Morales","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.omtn.2025.102759_bib288","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170185","article-title":"Improved mitochondrial function in the hearts of sarcolipin-deficient dystrophin and utrophin double-knockout mice","volume":"9","author":"Mareedu","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102759_bib289","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41467-017-01146-7","article-title":"Reducing sarcolipin expression mitigates Duchenne muscular dystrophy and associated cardiomyopathy in mice","volume":"8","author":"Voit","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib290","doi-asserted-by":"crossref","first-page":"C260","DOI":"10.1152\/ajpcell.00125.2021","article-title":"Reducing sarcolipin expression improves muscle metabolism in mdx mice","volume":"322","author":"Balakrishnan","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.omtn.2025.102759_bib291","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/ars.2011.3964","article-title":"Heme oxygenase-1 inhibits myoblast differentiation by targeting myomirs","volume":"16","author":"Kozakowska","year":"2012","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.omtn.2025.102759_bib292","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13395-024-00346-2","article-title":"Targeted expression of heme oxygenase-1 in satellite cells improves skeletal muscle pathology in dystrophic mice","volume":"14","author":"Florczyk-Soluch","year":"2024","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2025.102759_bib293","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00018-019-03006-7","article-title":"Targeting angiogenesis in Duchenne muscular dystrophy","volume":"76","author":"Podkalicka","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2025.102759_bib294","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/path.5704","article-title":"Dystrophin deficiency impairs vascular structure and function in the canine model of Duchenne muscular dystrophy","volume":"254","author":"Kodippili","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.omtn.2025.102759_bib295","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/biomedicines9050481","article-title":"Age-Dependent Dysregulation of Muscle Vasculature and Blood Flow Recovery after Hindlimb Ischemia in the mdx Model of Duchenne Muscular Dystrophy","volume":"9","author":"Podkalicka","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2025.102759_bib296","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0002-9440(10)63499-2","article-title":"Vascular Endothelial Growth Factor Modulates Skeletal Myoblast Function","volume":"163","author":"Germani","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2025.102759_bib297","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1096\/fj.07-8459com","article-title":"VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice","volume":"21","author":"Messina","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2025.102759_bib298","first-page":"1825","article-title":"Adeno-associated virus serotype 9 mediated vascular endothelial growth factor gene overexpression in mdx mice","volume":"15","author":"Song","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib299","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/gt.2014.13","article-title":"Sonic hedgehog gene therapy increases the ability of the dystrophic skeletal muscle to regenerate after injury","volume":"21","author":"Piccioni","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008468","article-title":"Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy","volume":"15","author":"Verma","year":"2019","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtn.2025.102759_bib301","doi-asserted-by":"crossref","first-page":"3","DOI":"10.12703\/r\/12-3","article-title":"Vascular therapy for Duchenne muscular dystrophy (DMD)","volume":"12","author":"Thapa","year":"2023","journal-title":"Fac. Rev."},{"key":"10.1016\/j.omtn.2025.102759_bib302","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/mus.26433","article-title":"Inhibition of microRNA-92a increases blood vessels and satellite cells in skeletal muscle but does not improve duchenne muscular dystrophy-related phenotype in mdx mice","volume":"59","author":"Verma","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2025.102759_bib303","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1007\/s00018-020-03537-4","article-title":"Noncoding RNAs in Duchenne and Becker muscular dystrophies: role in pathogenesis and future prognostic and therapeutic perspectives","volume":"77","author":"Brusa","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2025.102759_bib304","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/cvr\/cvz236","article-title":"miR-378a influences vascularization in skeletal muscles","volume":"116","author":"Krist","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.omtn.2025.102759_bib305","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135576","article-title":"Lack of miR-378 attenuates muscular dystrophy in mdx mice","volume":"5","author":"Podkalicka","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102759_bib306","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1038\/s41598-022-07868-z","article-title":"miR-378 affects metabolic disturbances in the mdx model of Duchenne muscular dystrophy","volume":"12","author":"Podkalicka","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102759_bib307","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s42003-021-01952-2","article-title":"MiR-199-3p enhances muscle regeneration and ameliorates aged muscle and muscular dystrophy","volume":"4","author":"Fukuoka","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omtn.2025.102759_bib308","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature11739","article-title":"Functional screening identifies miRNAs inducing cardiac regeneration","volume":"492","author":"Eulalio","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib309","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-019-1191-6","article-title":"MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs","volume":"569","author":"Gabisonia","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102759_bib310","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93309","article-title":"MicroRNA-29 overexpression by adeno-associated virus suppresses fibrosis and restores muscle function in combination with micro-dystrophin","volume":"2","author":"Heller","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102759_bib311","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add5275","article-title":"Thyroid-stimulating hormone receptor signaling restores skeletal muscle stem cell regeneration in rats with muscular dystrophy","volume":"15","author":"Taglietti","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102759_bib312","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/s41467-024-46187-x","article-title":"fhl2b mediates extraocular muscle protection in zebrafish models of muscular dystrophies and its ectopic expression ameliorates affected body muscles","volume":"15","author":"Dennhag","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102759_bib313","doi-asserted-by":"crossref","first-page":"C476","DOI":"10.1152\/ajpcell.00456.2008","article-title":"Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice","volume":"296","author":"Martin","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.omtn.2025.102759_bib314","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2019.01.005","article-title":"rAAVrh74.MCK.GALGT2 Protects against Loss of Hemodynamic Function in the Aging mdx Mouse Heart","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102759_bib315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248721","article-title":"Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength","volume":"16","author":"Martin","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102759_bib316","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2022.08.009","article-title":"A first-in-human phase I\/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2","volume":"27","author":"Flanigan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102759_bib317","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtn.2025.102759_bib318","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41591-022-01889-x","article-title":"Early treatment is a lifeline for infants with SMA","volume":"28","author":"Sumner","year":"2022","journal-title":"Nat. Med."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:12:44Z","timestamp":1773331964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":316,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125003130"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102759","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic strategies for therapy of Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102759"}}